Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio, 8-K earnings release, 10-Q stay in one workspace.
Earnings call · FY2026 Q2
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio, 8-K earnings release, 10-Q stay in one workspace.
Management tone
Positive
Net tone +35 · moderate hedging
Forward guidance
5 guided metrics
Management's latest ranges and targets are included below.
Research coverage
4 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
From the 8-K filed Aug 13, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Consolidated revenue
Maintained
full-year 2026
|
$325M – $345M | — | |
|
Adjusted EBITDA
Raised
full-year 2026
|
$125M – $140M | Non-GAAP | |
|
Cash OpEx
Lowered
full-year 2026
|
$145M – $155M | — |
Stated verbally and extracted from the transcript.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Full-year adjusted EBITDA
Raised
full-year 2026
|
$125M – $140M | Non-GAAP | |
|
Cash-Up X guidance
full-year 2026
|
$145M – $155M | Non-GAAP |
How the reported period landed and where the business moved.
Good morning and welcome to the CORE Medics second quarter 2026 earnings and corporate update conference call. Today's conference call is being recorded. There will be a question and answer session at the end of today's presentation and instructions on how to ask a question will be given at that time. At this time, I would like to turn the conference call over to Dan Ferry from LifeSci Advisors. Please go ahead.
Good morning, and welcome to the CoreMedics Second Quarter 2026 Earnings and Corporate Update Conference Call. Leading the call today is Joe Tadisco, Chairman and Chief Executive Officer of CoreMedics. He is joined by Liz Hurlburt, EVP and Chief Operating and Commercial Officer, and Susan Blum, EVP and Chief Financial Officer. In addition, Beth Zelnick-Kaufman, EVP and Chief Legal and Compliance Officer and Corporate Secretary, and Dr. Matt David, EVP and Chief Business Officer, are on the line and will be available during the Q&A session. Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meeting set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management's expectations, beliefs, goals, and plans by the company's prospects and future financial position. Action results may differ materially from the estimates and projections on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in CoreMedx filings with the SEC, which are available free of charge at the SEC's website or upon request from CoreMedx. CoreMedx may not actually achieve the goals or plans described in these forward-looking statements. An investor should not place undue reliance on these statements. CoreMedx does not intend to update these forward-looking statements except as required by law. During this call, the company will discuss certain non-GAAP measures of its performance. GAP to non-GAAP financial reconciliations and supplemental financial information are provided in CoreMedx earnings release and the current report on Form 8K filed with the SEC. This information is also available on the Investor Relations section of CoreMedics' website. At this time, it is now my pleasure to turn the call over to Joe Tedisco, Chairman and Chief Executive Officer of CoreMedics. Joe, please go ahead.
Thank you, Dan. Good morning, everyone, and thank you for joining us on this call. In the second quarter, we continue to execute on our core strategic initiatives, solidifying the FENCAT's market position as we navigate the evolving post-DAPA landscape, meaningfully advancing our high-value pipeline, highlighted by the positive phase three respect data for Rizeo, and now working collaboratively with Mundi Farmer towards their submission of the SMBA for Rizeo in the prophylaxis of invasive fungal disease. And lastly, deploying our capital in a disciplined manner to fuel sustainable growth and new business development opportunities. We believe this combination of commercial execution, pipeline progression, and strategic capital allocation in positions core medics to drive long-term value for shareholders while building an increasingly diversified and resilient business. We announced this morning second quarter consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million. Susan will provide more granular details of second quarter financial results. Today we also announced that we've signed a multi-year commercial supply agreement for DefendCAT with an additional large dialysis organization or LDO. With this agreement, Cormedics now has commercial supply agreements in place with all five of the top dialysis providers in the U.S. The newly signed LDO has placed initial order and will initially begin a pilot of DefendCat in the third quarter of this year with a potential opportunity to expand utilization in 2027. We view the signing of this agreement as an important milestone and validation of DefendCat's clinical value proposition with the largest providers in the U.S. dialysis market. Turning to guidance, we are reaffirming our full-year 2026 revenue guidance with a range of $325 million to $345 million and raising our full-year adjusted EBITDA guidance to a new range of $125 million to $140 million. We will revisit guidance as the year progresses and as we gain additional visibility into post-ADAPA ordering pattern. While we're only a few weeks into the third quarter, Bankhead order volumes in July have tracked consistent with the post-ADAPA forecast underlying our financial guidance. In addition to the new LDO agreement, we have signed contract amendments with our major customers covering third and fourth quarter 2026 pricing, and in some instances, pricing and volume commitments for 2027. These amendments give us improved visibility into pricing and utilization through year-end and are designed to keep patients on therapy through the reimbursement transition. We continue to focus significant internal resources on the FENCAST growth strategy through Medicare Advantage contracting, and I'm pleased with the progress of those discussions to date. Contracting cycles with these plans can be lengthy, and we have not assumed a contribution for Medicare Advantage in our 2026 guidance. We continue to believe Medicare Advantage represents a meaningful long-term growth avenue for FENCAST. PANCAS clinical value and its potential for meaningful downstream cost savings continue to be supported by a growing body of real-world evidence that our partners are publishing, and we anticipate additional data presentations this fall at the American Society of Nephrology's Kidney Week and at ID Week. Turning to our pipeline, we announced this morning that we anticipate the submission of the SMDA to Reseo in prophylaxis in the third quarter of this year. This follows last quarter's announcement of positive preliminary top-line clinical trial results from the RESPECT study, a Phase III clinical study evaluating Reseo for the prophylaxis of invasive fungal disease in adult immunosuppressed patients undergoing allogeneic bone and marrow transplant. We believe these results position Reseo, if approved, to become an attractive option for clinicians in the prophylaxis of invasive fungal disease, or ISD. Assuming timely submission and FDA acceptance of the filing, we would anticipate agency action in the first half of 2027. As we begin to prepare our commercial infrastructure for a potential launch of Reseo for prophylaxis, we expect to incur incremental spend in the back half of the year, including the anticipated addition of 15 to 20 positions across both commercial and medical. These investments are sized to allow us to move quickly at approval while preserving flexibility of regulatory timeline shift and are already reflected in our narrowed full-year Cash-Up X guidance of $145 to $155 million. As a reminder, our Cash-Up X guidance excludes non-cash charges such as stock-based compensation. I would now like to turn the call over to our Chief Operating Commercial Officer, Liz Hurlburt, to provide an update on clinical activities. Liz, please go ahead.
Thank you, Joe, and good morning, everyone. As Joe mentioned, we were pleased to announce preliminary top-line results of the RESPECT study at the end of April and following a constructive pre-MDA meeting with the FDA, are working diligently with our partner Mundy Pharma in support of their submission of the FNDA for Reseo in prophylaxis in the third quarter. As a reminder, the RESPECT study met its primary endpoint for FDA of fungal-free survival at day 90, showing non-inferiority versus the standard antifungal regimen, or SAR, are, meeting the pre-specified non-inferiority margin. In addition, results showed a favorable profile across multiple secondary endpoints, most notably in the treatment of emergent adverse events leading to dose reduction, interruption, or withdrawal of study drugs and study discontinuation. As we've stated previously, the objective with the RESPECT study was to show comparable efficacy to standard of care while also demonstrating a favorable overall safety profile with regard to drug-drug interactions and toxicity. We believe the study has achieved this objective in that the results position Reseo, if approved, as a differentiated option for prophylaxis of ISD with a meaningful potential commercial opportunity. It's important to remember that this was a global study conducted by our partner, Mundy Pharma, who owns global IT rights and will pursue regulatory approvals outside of the United States. Mundy Pharma is currently the holder of the U.S. NDA, and under the terms of our agreement, transfers ownership of the NDA to Cormedics following approval of an SNDA for the prophylaxis indication, at which point Cormedics would own and control the U.S. assets. Under our agreement, the parties must work together on the publication of data and any submissions to FDA. In terms of data publication, we currently expect additional data from the Phase III RESPECT study to be published later this year at one or more medical conferences during the fourth quarter. Turning to DEFENDCAT, we also expect additional real-world evidence to be published in the fourth quarter, with multiple abstracts having been submitted to both ASN and ID Week. Assuming acceptance, these publications will present the final results from the U.S. Renal Care Real-World Evidence Study, which, at interim analysis, showed a meaningful impact on infection-related hospitalizations and catheter-related bloodstream infections, as well as two other external studies. The first will highlight the demonstrated efficacy of DEFENCAS when used in combination with chlorhexidine antimicrobial tests, and the second is expected to highlight the clinical and economic benefits of DEFENCAS in the outpatient hemodialysis setting related to a meaningful reduction in TPA use by facilities. All combined, we expect that these data will add to the growing body of evidence supporting the clinical and pharmacoeconomic value of Defedcast. Shifting gears to our Phase III TPN study, we recently submitted a protocol amendment to FDA that narrows certain exclusion criteria, which we believe can support increased enrollment in the coming months and we have additionally activated additional sites. We will continue to update investors on our progress as we move through the year and we continue to expect study completion in 2028. I would now like to turn the call over to Susan to discuss the company's second quarter financial results and financial position.
Susan. Thanks Liz and good morning everyone. We are pleased to announce our second quarter results which reflects strong execution across the business, continued demand for DefendCast, and the contribution from the acquired Melinda portfolio. As a reminder, because the Melinda acquisition closed in August 2025, the second quarter of 2026 and the third quarter of 2025, year-over-year comparisons are heavily influenced by the combined company. We also filed and encouraged investors to review it for a consolidated revenue was $101.9 million. Compared with $39.7 million, the revenue included $66.1 million in DEFENCAP sales.
The opportunity ahead of us. There are internal expectations at Tadapa expiration, demonstrating durable underlying utilization, which we believe positioned for value generator, following the reimbursing a pipeline of high-value late-stage opportunities, including Viseo for prophylaxis and DEFENCAP. And third, we have delivered significant profitability and cash generation, $277.8 million of adjusted EBITDA over the trailing 12 months, and $267 million of combined cash and investments at quarter end, which allows us to reinvest in growth and pursue business. We remain confident in our outlook for this year and our past-stained growth and profitability beyond it. This concludes our prepared remarks, and I'll ask the operator to open up now for questions.
We will now begin the question and answer session. To ask a question, you may press star then 1 on your touchtone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then 2. At this time, we will pause momentarily to assemble our roster. Our first question comes from Roana Ruiz with Leerink.
Please go ahead. hi guys this is anna on for roana uh thanks so much for taking our question and congrats on the progress just wanted to check in on how the new multi-year agreement with the ldo is expected to impact uh your 2027 expectations and if you could give any color on how long it takes for a new site to reach this steady state production in line with other operators um and i have a follow-up Okay.
Thanks, Anna. So, you know, we just recently signed that agreement and they're rolling out a pilot. We, you know, we're waiting to see kind of actually what they're looking for and we're hopeful for additional utilization. So once we get better visibility, you know, we'll be in a position probably to talk more about 2027. There's a lot of variables that go into 27 guidance. I don't expect we'll be in a position to comment on it until either late this year or early next year. You know, so there's just a lot of pushes and pulls. We don't have any cause now to either adjust the top or bottom, you know, of that guidance. But as we move through the year and we get better visibility, you know, we can provide updates. sure thanks um and is any of that uh lvo pilots included in the 2026 guidance uh no no um right now it's uh well obviously it's tracked in the revenue so it's within the the revenue that we're seeing from the pilot is within our existing guidance and um right for defend cath we are right now tracking to the kind of mid top part of of the defend cast guidance so So, you know, let's see where we go through the year, and as I said, we'll update, you know, as we go.
Great. Thanks so much.
Our next question comes from Leonid Timoshev with RBC Capital Markets. Please go ahead.
Hey, guys. Thanks for taking my question. I want to ask on maybe if you can comment on what you're seeing in terms of volume growth in the existing channels thus far in this quarter, just given that we're in the post-ADAPA period now. And then related to that, just as a follow-up, how are you thinking about the potential for the final ESRD guidance to increase the payment? Thanks.
All right. Thanks, Leo. So, look, in terms of volume growth, I think what we're seeing in July is really kind of stabilized volumes with the larger players, which is what we expected, and some attrition with the really small players, which is also what we expected. I think to really see volume growth in defend caps, one of two things is going to happen. The new LDO is going to have to come in meaningfully with some adoption and or Medicare Advantage contracting. I think we're cautiously optimistic we're making good progress that perhaps we have something in place that takes effect early next year and starts to really impact the FENCAT volume. Those are really the two levers that I see from the FENCAT standpoint. um now the the final uh esrd rule obviously they put out the proposed rule um it was a little bit different than what we were expecting in terms of the uh the quarterly mechanism i expect there's going to be a lot of comment on that um not sure if that's will actually what will make it into the final rule uh but you know we'll we'll expect the final rule in november and then you know just accordingly our next question comes from jason butler with citizens please go ahead
Hi, thanks for taking the questions. First one, can you give any more color on the size or scope of the pilot study being conducted by the new LBO? And then for Reseo and Prophy, can you talk about, you know, since you had the Phase III results, the feedback you're getting from potential prescribers, just what the reception to that data has been as you think about a potential label expansion?
Thank you. yeah look you know right now the size and scope of the pilot we we we've shipped initial order we think it's a couple hundred clinics you know we'll see where where we can go from there i don't want to get out over my skis on the on the pilot yet jason so we're just right now we're really happy to finally gotten right that ldo kind of uh over over the hump and and uh to to the point of commercialization so um you know we're taking that one day by day um on the zeo prophy the full data set is not yet out, so we really haven't been able to conduct a robust market research. As we said in the script, we are working with our partner, Mundi Pharma. We would expect it to be published later in the fourth quarter at one or more medical conferences, and once we have that data available, we'll be able to have more substantive discussions around the data itself with clinicians.
Great. Thank you.
Our next question comes from Serge Ballinger with Needham company. Please go ahead.
Hi, good morning. Thanks for taking a question. I guess first on the new LBO, first congratulations, even if it's just a pilot program. I guess my question is why did the LBO decide to enter an agreement now when the product's been available for two years and I I know the company had some meaningful efforts to sign them up. Secondly, on Roseo, following your FDA meeting, just curious what your expectations are for potential labeling of the product. I believe a Phase III trial was conducted in allogenic HSCT patients. Curious if you'll be able to address the broad patient population that could benefit from Roseo. Thanks.
Thanks, Serge. Look, I'm a new LDL. I really can't speak to the motivations of the company in terms of timing. Obviously, we have built a wealth of real-world evidence around the clinical efficacy and the pharmacoeconomic benefits of DefendCast. And as I said, we're happy that now they are choosing to begin implementation of DefendCast. On Roseo, look, it's going to be a label review issue. So until we work through this process, We don't, just coming out of the pre-NDA meeting, we don't have yet visibility of what the final label will be.
Our next question comes from Brandon Folks with H.C. Wainwright. Please go ahead.
Hi, thanks for taking my question, and congrats on the progress. Maybe just one from me. Can you just talk about the SG&A in the quarter and the updated guidance? You know, did you take any actions in the quarter, you know, whether it's – especially on the sales and marketing infrastructure, right, just on DefendCats or the existing Malenta portfolio? Just any color there on the expense discipline on the SG&A line?
Thanks, Brandon. I'll let Susan comment. You know, we didn't take any deliberate actions. We're obviously turning a little bit light on the expense side. some of the staffing that we're bringing on is coming in later in the year.
Yeah, and also we did, and we disclosed this in our Form 10-Q, we had a reduction of G&A for $4.2 million in the quarter. So it's reflecting artificially low because of that. $2.7 million of that was incurred primarily in Q1 of 2026. So we added the deductible under our insurance policy. So we were able to claim the reimbursement of those, and that's what we recorded in the second quarter. So it essentially eliminates those litigation legal fees that we had incurred in Q1 and in Q2 during the second quarter. So if you think about the run rate for expenses, it would be $2.7 million higher because that makes sense.
It does. And then just to confirm, so, you know, there's been no actions taken on the DefendCast sales and marketing infrastructure ahead of sort of the lower re-investment period.
No, there's been no actions taken in the company. No, we're done.
Perfect. Thank you very much and congrats on the progress.
Oh, thank you. This concludes our question and answer session. Thank you for attending today's presentation. You may now disconnect.
The transcript preserves the spoken record. The company's filings state:
17:52 to 27:24 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Please go ahead. hi guys this is anna on for roana uh thanks so much for taking our question and congrats on the progress just wanted to check in on how the new multi-year agreement with the ldo is expected to impact uh your 2027 expectations and if you could give any color on how long it takes for a new site to reach…
Joe Todisco: Thanks, Anna. So, you know, we just recently signed that agreement and they're rolling out a pilot. We, you know, we're waiting to see kind of actually what they're looking for and we're hopeful for additional utilization. So once we get better visibility, you…
Hey, guys. Thanks for taking my question. I want to ask on maybe if you can comment on what you're seeing in terms of volume growth in the existing channels thus far in this quarter, just given that we're in the post-ADAPA period now. And then related to that, just as a follow-up, how are you thinking about the…
Joe Todisco: All right. Thanks, Leo. So, look, in terms of volume growth, I think what we're seeing in July is really kind of stabilized volumes with the larger players, which is what we expected, and some attrition with the really small players, which is also what we…
Hi, thanks for taking the questions. First one, can you give any more color on the size or scope of the pilot study being conducted by the new LBO? And then for Reseo and Prophy, can you talk about, you know, since you had the Phase III results, the feedback you're getting from potential prescribers, just what the…
Joe Todisco: Thank you. yeah look you know right now the size and scope of the pilot we we we've shipped initial order we think it's a couple hundred clinics you know we'll see where where we can go from there i don't want to get out over my skis on the on the pilot yet…
Hi, good morning. Thanks for taking a question. I guess first on the new LBO, first congratulations, even if it's just a pilot program. I guess my question is why did the LBO decide to enter an agreement now when the product's been available for two years and I I know the company had some meaningful efforts to sign…
Joe Todisco: Thanks, Serge. Look, I'm a new LDL. I really can't speak to the motivations of the company in terms of timing. Obviously, we have built a wealth of real-world evidence around the clinical efficacy and the pharmacoeconomic benefits of DefendCast. And as I said…
Hi, thanks for taking my question, and congrats on the progress. Maybe just one from me. Can you just talk about the SG&A in the quarter and the updated guidance? You know, did you take any actions in the quarter, you know, whether it's – especially on the sales and marketing infrastructure, right, just on DefendCats…
Joe Todisco: Thanks, Brandon. I'll let Susan comment. You know, we didn't take any deliberate actions. We're obviously turning a little bit light on the expense side. some of the staffing that we're bringing on is coming in later in the year.
Also speaking: Susan Blum
SEC filing · Item 2.02
Filed Aug 13, 2026 · complete as-filed document
SEC periodic report
Filed Aug 13, 2026 · complete as-filed document